Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 1889Carcinoma, Non-Small-Cell Lung 1350Prostatic Neoplasms 980Colorectal Neoplasms 851Multiple Myeloma 741Leukemia, Myeloid, Acute 725Neoplasms 691Lung Neoplasms 680Neoplasm Metastasis 642Lymphoma 579Carcinoma, Hepatocellular 571Pancreatic Neoplasms 567Stomach Neoplasms 523Leukemia 511Recurrence 493Leukemia, Lymphocytic, Chronic, B-Cell 459Precursor Cell Lymphoblastic Leukemia-Lymphoma 452Melanoma 451Lymphoma, Non-Hodgkin 443Ovarian Neoplasms 426Lymphoma, Large B-Cell, Diffuse 423Squamous Cell Carcinoma of Head and Neck 416Myelodysplastic Syndromes 416Head and Neck Neoplasms 404Brain Neoplasms 403Rectal Neoplasms 397Glioblastoma 375Carcinoma, Renal Cell 350Hodgkin Disease 338Esophageal Neoplasms 337

Interventions

Rituximab 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Infectious Mononucleosis × Clear all
NCT04138875 2022-06-23

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Yale University

Phase 2 Withdrawn
Other hematologic neoplasm

Infectious Mononucleosis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡